onr:"swepub:oai:DiVA.org:uu-472929"
Search: onr:"swepub:oai:DiVA.org:uu-472929" > Cytogenetics in Chr...
- 1 of 1
- Previous record
- Next record
- To hitlist
Cytogenetics in Chronic Lymphocytic Leukemia : ERIC Perspectives and Recommendations
-
- Baliakas, Panagiotis, 1977- (author)
- Uppsala universitet,Science for Life Laboratory, SciLifeLab,Experimentell och klinisk onkologi,Uppsala Univ Hosp, Dept Clin Genet, Uppsala, Sweden.
-
- Espinet, Blanca (author)
- Hosp del Mar, Mol Cytogenet Lab, Pathol Dept, Barcelona, Spain.;Inst Hosp del Mar Invest Med IMIM, Canc Res Program, Translat Res Hematol Neoplasms Grp, Barcelona, Spain.
-
- Mellink, Clemens (author)
- Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Clin Genet, Genom Lab, Amsterdam, Netherlands.
- show more...
- show less...
- (creator_code:org_t)
- Ovid Technologies (Wolters Kluwer Health), 2022
- 2022
- English.
- In: HemaSphere. - : Ovid Technologies (Wolters Kluwer Health). - 2572-9241. ; 6:4
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Mounting evidence underscores the clinical value of cytogenetic analysis in chronic lymphocytic leukemia (CLL), particularly as it allows the identification of complex karyotype, that has recently emerged as a prognostic and potentially predictive biomarker. That said, explicit recommendations regarding the methodology and clinical interpretation of either chromosome banding analysis (CBA) or chromosome microarray analysis (CMA) are still lacking. We herein present the consensus of the Cytogenetic Steering Scientific Committee of ERIC, the European Research Initiative on CLL, regarding methodological issues as well as clinical interpretation of CBA/CMA and discuss their relevance in CLL. ERIC considers CBA standardized and feasible for CLL on the condition that standards are met, extending from the use of novel mitogens to the accurate interpretation of the findings. On the other hand, CMA, is also standardized, however, robust data on its clinical utility are still scarce. In conclusion, cytogenetic analysis is not yet mature enough to guide treatment choices in CLL. That notwithstanding, ERIC encourages the wide application of CBA, and potentially also CMA, in clinical trials in order to obtain robust evidence regarding the predictive value of specific cytogenetic profiles towards refining risk stratification and improving the management of patients with CLL.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Baliakas, Panagi ...
- Espinet, Blanca
- Mellink, Clemens
- Jarosova, Marie
- Athanasiadou, An ...
- Ghia, Paolo
- show more...
- Kater, Arnon P.
- Oscier, David
- Haferlach, Claud ...
- Stamatopoulos, K ...
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Hematology
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- HemaSphere
- By the university
- Uppsala University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
